API | talnetant

talnetant Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions. Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued. ^Wikipedia

Chemistry

SMILES: CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1
InChIKey: BIAVGWDGIJKWRM-FQEVSTJZSA-N
Mol. Mass: 382.46
ALogP: 5.49 Partition coefficient
ChEMBL Molecule:
talnetant

More Chemistry

Pharmacology

Mechanism of Action:
- Neuromedin-K receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

n-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide | sb-2234 | sb 223412 | sb-223412 | talnetant

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Irritable Bowel Syndrome (Phase 2)

Schizophrenia (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue